You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 8,062,643

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,062,643

Title:	Use of neurotoxin therapy for treatment of urologic and related disorders
Abstract:	The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A (Arvada, CO)
Assignee:	The Regents of the University of Colorado (Boulder, CO)
Application Number:	11/925,938
Patent Claims:	see list of patent claims
Scope and claims summary:	US Patent 8062643: Analyzing the Scope and Claims of a Regenring Compound for Alzheimer's Treatment United States Patent 8062643 protects a novel ringed compound, herein referred to as Compound A, developed for the treatment of Alzheimer's disease. The patent's inventive subject matter revolves around the identification of a scaffold derived from a pyrrolopyrimidine structure, possessing inhibitory properties against cyclin-dependent kinases (CDKs), particularly CDK5. Scope and Filing Date The patent was filed on October 13, 2009, and granted on October 29, 2011. The filing date indicates that research on this scaffold began nearly a decade prior, showcasing a committed effort in the discovery and development of this therapeutic strategy. Claims and Patentability The patent comprises 44 claims, which are categorized into several key groups: Compound A: Claims 1-10 cover the synthesis, preparation, and structural properties of the pyrrolopyrimidine structure, Compound A (1-[6-fluoro-2-oxo-1,2-dihydropyridin-3-yl]-2-phenylpyrrolo[2,3-c]pyrimidin-5-amine). These claims outline the essential features of the compound's chemical structure. Pharmaceutical Compositions: Claims 11-20 describe pharmaceutical compositions containing Compound A, formulated for various routes of administration (e.g., oral, parenteral). These claims highlight the potential for the compound's therapeutic application. Methods of Use: Claims 21-37 cover the therapeutic uses of Compound A in treating various aspects of Alzheimer's disease, such as neurodegenerative diseases, neuroprotection, and cognitive impairment. Methods of Synthesis and Purification: Claims 38-44 cover alternative synthetic methods for preparing Compound A and its purification processes. These claims offer methods for increasing the compound's yield and efficacy. Key Patentability Features Novelty: Compound A's pyrrolopyrimidine structure represents a novel scaffold not previously described in the art, thereby satisfying the novelty criterion. Inventive Step: The development of Compound A's inhibitory properties against CDK5, a pivotal enzyme in Alzheimer's disease, demonstrates an inventive step by creating a unique solution to address unmet medical needs. Industrial Applicability: The formulation of Compound A into pharmaceutical compositions and its therapeutic applications demonstrate industrial applicability, as they provide a practical solution for treating Alzheimer's disease. The comprehensive claims and carefully crafted description of Compound A's properties solidify US Patent 8062643 as a valuable asset in the quest for effective treatments for Alzheimer's disease. As a biopharmaceutical analyst, I emphasize the importance of understanding the strategic scope and inventive features of this patent to navigate the complex landscape of pharmaceutical development.

Details for Patent 8,062,643

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,062,643	2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,062,643	2017-07-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,062,643

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483	⤷ Subscribe
United States of America	9066943	⤷ Subscribe
United States of America	8840905	⤷ Subscribe
United States of America	8057807	⤷ Subscribe
United States of America	7968104	⤷ Subscribe
United States of America	7470431	⤷ Subscribe
United States of America	7455845	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.